<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"><channel><title>The serious complications of GLP-1s that few may know about — Live Feed</title><link>https://www.live-feeds.com/feed/the-serious-complications-of-glp-1s-that-few-may-know-about</link><atom:link xmlns:atom="http://www.w3.org/2005/Atom" href="https://www.live-feeds.com/feed/the-serious-complications-of-glp-1s-that-few-may-know-about/rss.xml" rel="self" type="application/rss+xml"/><description>Continuously updated, source-cited coverage.</description>
<item><title>FDA mandates new eye-risk warning on GLP-1 drugs including Ozempic, Wegovy, Zepbound</title><link>https://www.live-feeds.com/feed/the-serious-complications-of-glp-1s-that-few-may-know-about</link><guid isPermaLink="false">https://www.live-feeds.com/feed/the-serious-complications-of-glp-1s-that-few-may-know-about#u209905</guid><pubDate>Fri, 20 Nov 2026 06:26:14 +0000</pubDate><description>The U.S. Food and Drug Administration has ordered manufacturers to add a warning about a rare but serious eye condition called non-arteritic anterior ischemic optic neuropathy (NAION) to the labels of roughly a dozen GLP-1 receptor agonists. The requirement covers widely used diabetes and weight-loss medications such as Novo Nordisk&amp;#039;s Ozempic and Wegovy (semaglutide) and Eli Lilly&amp;#039;s Zepbound and Mounjaro (tirzepatide). The agency said the condition can cause sudden vision loss and that patients should be advised to seek immediate medical attention if visual changes occur.Why it matte</description></item>
</channel></rss>